{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:36:25Z","timestamp":1776868585693,"version":"3.51.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Adelaide University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40261-026-01546-y","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:58:33Z","timestamp":1774688313000},"page":"531-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alternative Dosing Strategies to Enhance the Absorption of N-Acetyl-d-Mannosamine Monohydrate (ManNAc) in Healthy Adult Males"],"prefix":"10.1007","volume":"46","author":[{"given":"Tahlia R.","family":"Meola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kellie","family":"La Fontaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Condon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Wabnitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Fornasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan M.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-7287","authenticated-orcid":false,"given":"Stephanie E.","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"8","key":"1546_CR1","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/humu.22583","volume":"35","author":"FV Celeste","year":"2014","unstructured":"Celeste FV, Vilboux T, Ciccone C, et al. Mutation update for GNE gene variants associated with GNE myopathy. Hum Mutat. 2014;35(8):915\u201326.","journal-title":"Hum Mutat"},{"issue":"5","key":"1546_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.nmd.2014.03.004","volume":"24","author":"M Huizing","year":"2014","unstructured":"Huizing M, Carrillo-Carrasco N, Malicdan MCV, et al. GNE myopathy: new name and new mutation nomenclature. Neuromuscul Disord. 2014;24(5):387\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"1546_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1136\/jnnp-2013-307051","volume":"86","author":"I Nishino","year":"2015","unstructured":"Nishino I, Carrillo-Carrasco N, Argov Z. GNE myopathy: current update and future therapy. J Neurol Neurosurg Psychiatry. 2015;86(4):385.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"39","key":"1546_CR4","doi-asserted-by":"publisher","first-page":"24319","DOI":"10.1074\/jbc.272.39.24319","volume":"272","author":"R St\u00e4sche","year":"1997","unstructured":"St\u00e4sche R, Hinderlich S, Weise C, et al. A bifunctional enzyme catalyzes the first two steps in N-Acetylneuraminic Acid biosynthesis of rat liver. J Biol Chem. 1997;272(39):24319\u201324.","journal-title":"J Biol Chem"},{"issue":"39","key":"1546_CR5","doi-asserted-by":"publisher","first-page":"24313","DOI":"10.1074\/jbc.272.39.24313","volume":"272","author":"S Hinderlich","year":"1997","unstructured":"Hinderlich S, St\u00e4sche R, Zeitler R, et al. A bifunctional enzyme catalyzes the first two steps in N-Acetylneuraminic acid biosynthesis of rat liver. J Biol Chem. 1997;272(39):24313\u20138.","journal-title":"J Biol Chem"},{"issue":"4","key":"1546_CR6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.nurt.2008.07.004","volume":"5","author":"Z Argov","year":"2008","unstructured":"Argov Z, Mitrani-Rosenbaum S. The hereditary inclusion body myopathy enigma and its future therapy. Neurotherapeutics. 2008;5(4):633\u20137.","journal-title":"Neurotherapeutics"},{"issue":"12","key":"1546_CR7","doi-asserted-by":"publisher","first-page":"11402","DOI":"10.1074\/jbc.M313171200","volume":"279","author":"S Noguchi","year":"2004","unstructured":"Noguchi S, Keira Y, Murayama K, et al. Reduction of UDP-N-acetylglucosamine 2-epimerase\/N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles. J Biol Chem. 2004;279(12):11402\u20137.","journal-title":"J Biol Chem"},{"issue":"1","key":"1546_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/ng718","volume":"29","author":"I Eisenberg","year":"2001","unstructured":"Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase\/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet. 2001;29(1):83\u20137.","journal-title":"Nat Genet"},{"issue":"1","key":"1546_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/glycob\/2.1.25","volume":"2","author":"A Varki","year":"1992","unstructured":"Varki A. Diversity in the sialic acids. Glycobiology. 1992;2(1):25\u201340.","journal-title":"Glycobiology"},{"issue":"4","key":"1546_CR10","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1007\/s13311-018-0671-y","volume":"15","author":"N Carrillo","year":"2018","unstructured":"Carrillo N, Malicdan MC, Huizing M. GNE myopathy: etiology, diagnosis, and therapeutic challenges. Neurotherapeutics. 2018;15(4):900\u201314.","journal-title":"Neurotherapeutics"},{"issue":"6","key":"1546_CR11","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nm.1956","volume":"15","author":"MCV Malicdan","year":"2009","unstructured":"Malicdan MCV, Noguchi S, Hayashi YK, et al. Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. Nat Med. 2009;15(6):690.","journal-title":"Nat Med"},{"issue":"4","key":"1546_CR12","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ymgme.2012.10.011","volume":"107","author":"TK Niethamer","year":"2012","unstructured":"Niethamer TK, Yardeni T, Leoyklang P, et al. Oral monosaccharide therapies to reverse renal and muscle hyposialylation in a mouse model of GNE myopathy. Mol Genet Metab. 2012;107(4):748\u201355.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"1546_CR13","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1172\/JCI30954","volume":"117","author":"B Galeano","year":"2007","unstructured":"Galeano B, Klootwijk R, Manoli I, et al. Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. J Clin Invest. 2007;117(6):1585\u201394.","journal-title":"J Clin Invest"},{"issue":"2\u20133","key":"1546_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10719-006-9019-7","volume":"24","author":"D Gagiannis","year":"2007","unstructured":"Gagiannis D, Orthmann A, Danssmann I, et al. Reduced sialylation status in UDP-N-acetylglucosamine-2-epimerase\/N-acetylmannosamine kinase (GNE)-deficient mice. Glycoconj J. 2007;24(2\u20133):125\u201330.","journal-title":"Glycoconj J"},{"issue":"1\u20132","key":"1546_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ymgme.2017.04.010","volume":"122","author":"X Xu","year":"2017","unstructured":"Xu X, Wang AQ, Latham LL, et al. Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy. Mol Genet Metab. 2017;122(1\u20132):126\u201334.","journal-title":"Mol Genet Metab"},{"key":"1546_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70292","author":"TR Meola","year":"2025","unstructured":"Meola TR, Ludbrook G, Fornasini G, et al. Absolute bioavailability and intravenous pharmacokinetics of N-acetyl-D-mannosamine in humans. Br J Clin Pharmacol. 2025. https:\/\/doi.org\/10.1002\/bcp.70292.","journal-title":"Br J Clin Pharmacol"},{"key":"1546_CR17","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1038\/s41436-021-01259-x","volume":"23","author":"N Carrillo","year":"2021","unstructured":"Carrillo N, Malicdan MC, Leoyklang P, et al. Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study. Genet Med. 2021;23:2067\u201375.","journal-title":"Genet Med"},{"key":"1546_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1433","author":"AM Evans","year":"2024","unstructured":"Evans AM, Fornasini G, Meola TR, et al. Impact of food on the oral absorption of N-Acetyl-D-Mannosamine in healthy men and women. Clin Pharmacol Drug Dev. 2024. https:\/\/doi.org\/10.1002\/cpdd.1433.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"1546_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jps.2600550305","volume":"55","author":"G Levy","year":"1966","unstructured":"Levy G, Jusko WJ. Factors affecting the absorption of riboflavin in man. J Pharm Sci. 1966;55(3):285\u20139.","journal-title":"J Pharm Sci"},{"issue":"9","key":"1546_CR20","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.lfs.2004.10.016","volume":"76","author":"S Tazawa","year":"2005","unstructured":"Tazawa S, Yamato T, Fujikura H, et al. SLC5A9\/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci. 2005;76(9):1039\u201350.","journal-title":"Life Sci"},{"issue":"2","key":"1546_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mam.2012.07.001","volume":"34","author":"M Mueckler","year":"2013","unstructured":"Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013;34(2):121\u201338.","journal-title":"Mol Aspects Med"},{"issue":"3","key":"1546_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.febslet.2011.12.027","volume":"586","author":"R Grempler","year":"2012","unstructured":"Grempler R, Augustin R, Froehner S, et al. Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter. FEBS Lett. 2012;586(3):248\u201353.","journal-title":"FEBS Lett"},{"issue":"11","key":"1546_CR23","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.3748\/wjg.v12.i11.1657","volume":"12","author":"LA Drozdowski","year":"2006","unstructured":"Drozdowski LA, Thomson ABR. Intestinal sugar transport. World J Gastroenterol. 2006;12(11):1657\u201370.","journal-title":"World J Gastroenterol"},{"key":"1546_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jchromb.2015.07.018","volume":"1000","author":"Y Shi","year":"2015","unstructured":"Shi Y, Xu X, Fang M, et al. Quantitative hydrophilic interaction chromatography\u2013mass spectrometry analysis of N-acetylneuraminic acid and N-acetylmannosamine in human plasma. J Chromatogr B. 2015;1000:105\u201311.","journal-title":"J Chromatogr B"},{"issue":"2","key":"1546_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733\u201394.","journal-title":"Physiol Rev"},{"issue":"3","key":"1546_CR26","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/pro.2858","volume":"25","author":"D Deng","year":"2016","unstructured":"Deng D, Yan N. GLUT, SGLT, and SWEET: structural and mechanistic investigations of the glucose transporters. Protein Sci. 2016;25(3):546\u201358.","journal-title":"Protein Sci"},{"issue":"1","key":"1546_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12551-015-0186-2","volume":"8","author":"AM Navale","year":"2016","unstructured":"Navale AM, Paranjape AN. Glucose transporters: physiological and pathological roles. Biophys Rev. 2016;8(1):5\u20139.","journal-title":"Biophys Rev"},{"issue":"1","key":"1546_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1079\/BJN2002763","volume":"89","author":"IS Wood","year":"2003","unstructured":"Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr. 2003;89(1):3\u20139.","journal-title":"Br J Nutr"},{"issue":"2","key":"1546_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","volume":"1","author":"AA Tahrani","year":"2013","unstructured":"Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1(2):140\u201351.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"1546_CR30","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1080\/10408398.2020.1784841","volume":"61","author":"W Liu","year":"2021","unstructured":"Liu W, Jin Y, Wilde PJ, et al. Mechanisms, physiology, and recent research progress of gastric emptying. Crit Rev Food Sci Nutr. 2021;61(16):2742\u201355.","journal-title":"Crit Rev Food Sci Nutr"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01546-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01546-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01546-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:39:48Z","timestamp":1776865188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01546-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1546"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01546-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.F. is a former employee of Leadiant Biosciences. A.M.E. and S.E.R. received institutional research funding by Leadiant Biosciences for the conduct of the clinical trial and pharmacokinetic analysis associated with this work. T.R.M., K.L.F., J.C. and P.W. declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"The clinical trial and pharmacokinetic analysis were funded by Leadiant Biosciences, Inc. Leadiant Biosciences, Inc. provided input into the study design; however, they were not involved in data collection, analysis or interpretation. No funding was received for manuscript preparation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"T.R.M., K.L.F., A.M.E., G.F. and S.E.R. conceived and designed the work; T.R.M., K.L.F., J.C., P.W. and S.E.R. acquired the data; T.R.M. analysed the data; T.R.M., A.M.E. and S.E.R. interpreted the data; T.R.M., A.M.E. and S.E.R. drafted the manuscript. All authors critically reviewed the manuscript for important intellectual content and approved the final version to be published. J.C. and P.W. were the clinical investigators for this study and had direct clinical responsibility for the participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The clinical trial was reviewed and approved by the University of South Australia Human Research Ethics Committee (Reference: 203235). The study was conducted in accordance with the Declaration of Helsinki and applicable local regulations.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Study participants were fully informed of the study procedures and provided written informed consent prior to study initiation.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}]}}